Melanotan I
Also known as afamelanotide · MT-1 · Melanotan-1
Regulated as a drug in at least one jurisdiction. Not described here as a treatment.
Melanotan I is the research-market name for afamelanotide, a synthetic analogue of alpha-melanocyte-stimulating hormone; the approved drug form is the SCENESSE implant.
More
Research reference, not advice. Amiravo sells nothing; some links are referrals.Read the full notice
What it is
Melanotan I and afamelanotide are the same 13-amino-acid peptide ([Nle4, D-Phe7]-alpha-MSH). Under the name afamelanotide it is FDA-approved as SCENESSE, a 16 mg subcutaneous implant, for adults with erythropoietic protoporphyria [1, 2]. Research-market Melanotan I is sold as a lyophilized powder and is not the approved product.
Where the evidence is
All controlled human data come from trials of the afamelanotide implant [4]. The full reference entry, including label dosing, adverse events and regulatory status, is on the afamelanotide page.
What is not known
No controlled studies of research-grade lyophilized Melanotan I were found. Purity, identity and stability of research-market material are not established by the approved-drug data.
Melanotan I draw calculator
Pick the vial strength and how much water is added, then enter an amount to see the units to draw. Arithmetic only, not a recommendation.
Computed from your inputs. Not a dose or a recommendation.
Compare water volumes for this vialShow
More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.
| Water | mg/mL | Draw |
|---|---|---|
| 0.5 mL | 20 | — |
| 1 mL | 10 | — |
| 1.5 mL | 6.667 | — |
| 2 mL | 5 | — |
| 2.5 mL | 4 | — |
| 3 mL | 3.333 | — |
| 5 mL | 2 | — |
Background viewing
We haven't found a clinician video focused on Melanotan I yet. Meanwhile, this widely watched talk covers the science of aging in general. It does not discuss Melanotan I.
These creators are not affiliated with Amiravo and do not endorse Amiravo or any product linked on this site. Nothing here is medical advice. Video views counted on YouTube as of Oct 24, 2026.
Key findings from the literature
Summarized from the abstracts of the references below. Study models are stated so findings are not overgeneralized.
Revision history
Meaningful changes to this entry, with dates and sources. Last reviewed Oct 23, 2026. Typo and layout fixes are not listed.
No recorded changes since the change log began on Oct 23, 2026.
References
- SCENESSE (afamelanotide) implant, for subcutaneous use. Prescribing information, CLINUVEL Inc. (SPL published May 13, 2026) DailyMed (FDA label). 2026
- Drugs@FDA application record for SCENESSE (afamelanotide), NDA 210797, original approval 8 October 2019 openFDA / Drugs@FDA. 2026
- Scenesse (afamelanotide): EPAR, medicine overview (authorised 22 December 2014 under exceptional circumstances) European Medicines Agency. 2026
- Afamelanotide for Erythropoietic Protoporphyria N Engl J Med. 2015
Last reviewed October 23, 2026 by the Amiravo editorial team.
Need the math?
Laboratory arithmetic with every formula shown.
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page is educational and is not medical advice.
Unbranded reference image. Amiravo does not produce, supply or sell this compound.
Specifications
- Format
- Lyophilized vial
- Type
- Single compound
Chemical identifiers are shown only when verified against PubChem.
Follow Melanotan I
See every new citation, evidence-grade or status change and correction in My Research, with optional email alerts. Free account.
